SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Undisclosed

            Therapeutic Area: Vaccines Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $516.0 million Upfront Cash: $438.0 million

            Deal Type: Acquisition October 01, 2020

            Details:

            Ligand gains a proprietary platform which uses P. fluorescens bacterium, which are especially well-suited for complex, large-scale protein production that cannot be made by more traditional host systems.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Undisclosed

            Therapeutic Area: Vaccines Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $516.0 million Upfront Cash: $438.0 million

            Deal Type: Acquisition August 10, 2020

            Details:

            Acquisition of Pfenex is expected to contribute a range of strategic benefits to Ligand like access to a proprietary, protein expression technology, utilized in various commercial and development-stage biopharmaceutical programs. Versatile operating business and among others.